Management of chronic thromboembolic pulmonary hypertension (CTEPH) includes multimodal therapy that depends on expert ...

Long-term exposure to very high altitude significantly reduces cardiopulmonary function in healthy adults from lowland ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...

After having demoed the ability to target high-altitude balloons using fighters, the French Air and Space Force will test the capacity at even higher altitudes.

BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.

Shares of Insmed jumped Tuesday after the biopharmaceutical firm reported positive results from a Phase 2 trial for its treatment of pulmonary arterial hypertension.

Higher all-cause and cardiovascular mortality predicted with concurrent hypertension and type 2 diabetes.

The aim: to reflect on the current state of pulmonary hypertension (PH) in Latin America. Though this serious disease affects only about 1% of the global population, it brings debilitating ...

Liquidia announces FDA approval and commercial launch of YUTREPIA for treating pulmonary arterial hypertension and PH-ILD.

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease.